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Summary 
Weekly low dose mitoxantrone (3 mg/m 2) plus doxorubicin (8 rag/m-') was administered assecond-line che- 
motherapy to 33 patients with advanced breast cancer. Four out of 28 evaluable patients (14%) obtained a
partial response with a median duration of 34 weeks (range 18-67 + weeks), while 8 patients (29%) showed 
stable disease with a median duration of 28 weeks (range 11+-60 weeks). Gastrointestinal toxicity and alope- 
cia were mild. Grade II and III leukopenia occurred in 63% of the courses without serious infectious disease. 
Four patients experienced an asymptomatic drop of 16-20% in the left ventricular ejection fraction (LVEF) 
after relatively low cumulative doses of each drug, and one patient with a history of pericarditis carcinoma- 
rosa and mediastinal irradiation developed a heart failure. In conclusion, this second-line combination treat- 
ment had moderate activity in breast cancer and caused only few subjective side effects, especially with 
respect to gastrointestinal symptoms. 
Introduction 
Combination chemotherapy appears to be more ef- 
fective than single agent therapy in inducing re- 
sponses in disseminated breast cancer. First-line 
treatment with cyclophosphamide, methotrexate, 
and fluorouracil (CMF) induces a response in 
about 40-50% of the patients with a median dura- 
tion of response of less than a year [1]. Second-line 
chemotherapy in CMF-refractory patients often 
consists of single agent treatment with (4'-epi-) 
doxorubicin or mitoxantrone in a 3-weekly high- 
dose schedule. However, only about 20-30% of 
these patients achieve a remission, frequently of 
short duration, while toxicity is often considerable 
especially by treatment with anthracyclines [2-4]. 
When (4'-epi-)doxorubicin or mitoxantrone are 
administered in low dose schedules every week or 
twice a month, the drugs can still be active, with 
remission rates of about 30% (0-59%) in patients 
with advanced breast cancer [5-22]. Gastrointesti- 
nal toxicity and alopecia re significantly less with 
these low-dose schedules. 
Cardiotoxicity is a major problem of long-term 
(4'-epi-)doxorubicin treatment, while mitoxan- 
trone occasionally produces uch toxicity. Doxo- 
rubicin cardiotoxicity is probably induced by the 
intracellular formation of free radicals and stim- 
ulation of membrane lipid peroxidation i the heart 
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muscle cells [23]. In experimental studies with 
hearts of rats, evidence was found that mitoxan- 
trone did not form free radicals, and had a strong 
inhibitory effect on the lipid peroxidation [24, 25]. 
In addition mitoxantrone was found to cause a con- 
centration-dependent inhibition of doxorubicin- 
stimulated lipid peroxidation i  liver microsomes 
of rabbits [26]. These data suggest hat mitoxan- 
trone might have an inhibitory effect on the occur- 
rence of doxorubicin-induced cardiotoxicity. Fur- 
thermore, low-dose schedules of doxorubicin 
seem to produce less cardiotoxicity [5, 6, 27, 28]. 
In view of these data it appeared attractive to com- 
bine doxorubicin and mitoxantrone atweekly dos- 
ages. Therefore, we initiated a phase II study with 
the combination of low doses of doxorubicin and 
mitoxantrone in a weekly schedule as second-line 
chemotherapy for patients with advanced breast 
cancer. 
Patients and methods 
Eligibility criteria of the protocol included: pa- 
tients with measurable or evaluable lesions, age 
less than 80 years, World Health Organization 
(WHO) performance score 2 or less, life expectan- 
cy of more than 2 months, serum bilirubin less than 
40gmol/1, WBC above 3.0x 109/1, platelets above 
100x 109/1, no prior therapy with anthracyclines or
mitoxantrone. Patients with a history of recent car- 
diac disease or with metastases in the central nerv- 
ous system were excluded. Metastatic disease of 
all patients had to be resistant o previous endo- 
crine therapy and to firstqine chemotherapy with 
CMF (cyclophosphamide, methotrexate, and fluo- 
rouracil). The protocol (DDHK 88-18) was ap- 
proved by 2 different committees, both a protocol 
review and a medical ethics committee. All pa- 
tients gave oral informed consent before entering 
the study. 
On-study evaluation consisted of medical histo- 
ry, physical examination, tumor measurements, 
complete blood count (Hb, WBC, platelets), auto- 
mated blood chemistry, left ventricular ejection 
fraction (LVEE using radionuclide multigated 
analysis with intervals of initially 12, subsequently 
8 or 4 weeks), bone scan, bone and chest x-rays, 
and liver CT-scan (in case of liver metastases). 
Treatment consisted of mitoxantrone 3mg/m 2
plus doxorubicin 8mg/m 2 as weekly sequential in- 
travenous injections via  running infusion with 
physiologic saline during a few minutes. Re- 
sponses were defined according to WHO criteria. 
Duration of partial response was measured from 
initiation of therapy until time of tumor progres- 
sion. Drug toxicity was also evaluated according to 
WHO criteria. 
Results 
Patient characteristics are indicated in Table 1. 
Thirty-three patients entered the study. Twenty- 
eight patients were evaluable for response and tox- 
icity. Five patients were not evaluable because of 
early withdrawal or lack of response valuation 
(within the first 8 weeks). Reasons to stop the treat- 
ment were: patient refusal (2), radiation therapy for 
pain (l), discovery of brain metastasis 1 week after 
start of treatment (1), and hyperbilirubinemia 1 
week after start of treatment (1). These 5 inevalua- 
ble patients died between 0.5 and 8 months after 
start of treatment. 
Responses are shown in Table 2. No complete 
responses were observed. A partial response (PR) 
was achieved in 4 out of 28 patients (t4%) with a 
median duration of 34 weeks (range 18-67 + 
weeks), while 8 patients (29%) showed stable dis- 
ease (SD) with a median duration of 28 weeks 
Table 1. Patient characteristics 
Number ot' patients entered: 33 




peri or unknown 6 
Age: 
median (range) 57 (40-74) 
WHO performance status: 
median (range) I (0-2) 
Metastatic sites per patient: 
median (range) 3 (1-4) 
t -  
(range l 1+-60 weeks). One patient had early pro- 
gressive disease after 2 weeks of treatment. Fifteen 
other patients howed tumor progression within 5- 
14 weeks after start of treatment. Progression-free 
survival and overall survival curves of the evalua- 
ble patients are shown in Fig. 1. Toxicity is present- 
ed in Table 3. Leukopenia grade II occurred in 48% 
and grade III in 15% of all cycles. Gastrointestinal 
toxicity was very mild. Serious hair loss grade II 
and III occurred in only a minority of the patients, 
and was probably still related to the previous CMF 
treatment. 
In 10 of the 12 patients who achieved a PR or SD, 
LVEF was repeated at least once. Three patients 
received a 'doxorubicin equivalent' dose (cumu- 
lative doxorubicin dose+ cumulative mitoxan- 
trone dosex 5) of more than 550mg/m 2,i.e. 720, 
795, and 850mg/m 2. LVEF of these patients drop- 
ped from 65 to 53%, 76 to 61%, and 80 to 73%, 
respectively. LVEF of two other patients receiving 
a cumulative 'doxorubicin equivalent' dose of 195 
and 292mg/m -~dropped from 89 to 75% and from 
76 to 64% respectively. In four other patients treat- 
ed with 'doxorubicin equivalent' cumulative doses 
of 209 to 500mg/m 2,LVEF remained stable to the 
baseline value. Thus, in none of these 9patients did 
LVEF decrease to below the critical imit of 50%, 
and none of them showed any clinical sign of car- 
diotoxicity. 
One patient, with previous mediastinal irradia- 
tion and pericarditis carcinomatosa, developed a 
cardiac failure in the presence of a drop in the abso- 
lute level of the LVEF from 78% to 29%, after be- 
ing treated with a 'doxorubicin equivalent' cumu- 
lative dose of 478mg/m 2. She was successfully 
treated with digoxin and iuretics. 
Table 2. Type of responses and time to progression (WHO criteria) 
Number of patients Mean duration in weeks 
(%) (range) 
CR 0 
PR 4 (14) 34 ( 18-67 +) 
SD 8 (29) 28 (I 1+-60) 
PD 16 (57) within 2-14 weeks 
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Fig. 1. Progression-free and overall survival of all evaluable patients 
measured in weeks from start of treatment. 
Discussion 
Several studies have shown that chemotherapy 
with weekly low doses of (4'-epi-)doxorubicin or 
mitoxantrone can be as effective as the 3-weekly 
high-dose schedules in inducing remissions in pa- 
tients with advanced breast cancer, whereas toxic- 
ity of the low doses is considerable ss [5-22, 27, 
28]. Treatment results of 18 studies using 'weekly' 
low dose (4'-epi-)doxorubicin or mitoxantrone in 
patients with advanced breast cancer are shown in 
Tables 4 and 5. Table 4 summarizes the treatment 
results of 7 studies concerning a total of 311 pa- 
tients of whom less than 50% had been treated be- 
fore with chemotherapy for advanced isease. 
Overall, 93 of the 311 patients (30%) treated with 
weekly low-dose anthracycline or mitoxantrone 
Table 3. Percentage of side effects (WHO grading) 
Grade 0 I 2 3 
Leukopenia* 15 22 48 15 
Thrombocytopenia* 80 9 9 2 
Mucositis* 96 4 - 
Diarrhea* 94 6 - - 
Nause',dVomiting* 84 1 l 5 - 
Alopecia** 82% 18% 
*Percentage of courses with side effect events as recorded in all 
(100%) weekly chemotherapy courses. 
** Alopecia is expressed as the percentage of patients experiencing 
various grades (0/I and 2/3) of hair loss. 
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Table 4. Low-dose doxorubicin (Dox), 4'-epi-doxorubicin (Epbdox), or mitoxantrone (Novantrone) mainly used as first-line chemotherapy in 
advanced breast cancer 
Drug Dosage Treatment interval Number of eval. Responses (CR/PR) Prior chemother. Ref. 
(weeks) pts (% pts) 
(n) (%) 
Dox 15 or 20rag 1 
Dox 20 mg l 
vs 
VAC 
Dox 20 mg 1 
vs 
Epi-dox 50 mg 
Epi-dox 12 mg/m 2 1 
Epi-dox 20 or 40 mg 1 
Epi-dox 20 mg 1 
Novantrone 3.3-6 mg/m 2 1 
50 7 14 44 (5) 
62 19 31 0 (6) 
3 66 24 35 
81 29 36 0 (7) 
2 68 15 22 
42 18 43 12 (8) 
25 12 48 <24 (9) 
41 4 10 17 (10) 
10 4 40 0 i l l )  
Number of eval. patients: 311. 
Number of patients achieving CR/PR: 93/311 (30%). 
Mean % CR/PR of all 7 individual series: 32% (range 10-48%). 
responded objectively. The mean percentage of re- 
sponse of the 7 separate series of patients was 32% 
(range 10-48%). Table 5 shows the treatment re- 
sults of 11 studies concerning 361 patients of whom 
more than 50% had been pretreated with various 
types of chemotherapy. During this second-line 
chemotherapy 110 out of 361 patients (30%) re- 
sponded. The mean percentage of response of the 
individual series was 29% (range 0-59%). Re- 
sponse durations in the studies vary widely. Based 
on response data available in 12 of these 18 studies, 
the median duration of response is about 6-7 
months. 
In our study we combined mitoxantrone and 
Table 5. Low-dose doxorubicin (Dox) or 4'-epi-doxorubicin (Epi-dox) mainly used as second-line chemotherapy in advanced breast cancer 
Drug Dosage Treatment interval Number of eval. pts Responses (CR/PR) Prior chemother. 
(weeks) (% pts) 
(n) (%) 
Ref. 
Dox 0.4 mg/kg* 
Dox 0.5-1 mgAg 
Dox 20 mg/m 2
Dox 6-- 12 mg/m ~ 
Dox 5-11.5 mg/m'- 
Dox 8-12 mg/m ~- 
Dox 10 mg/m 2
Dox 12 mg/m 2
Dox 20rag 
Epi-dox 20rag 




29 11 38 lO0 (12) 
31 I1 35 heavily pretreated (13) 
60 16 27 87 (14) 
34 20 59 >62 (15) 
20 3 15 lO0 (16) 
17 2 12 70 (17) 
24 0 0 >96 (18) 
30 8 27 97 (19) 
48 9 19 56 (20) 
39 20 51 51 (21) 
29 10 34 52 (2~) 
Number of eval. patients: 361. 
Number of patients achieving CR/PR: 110/361 (30%). 
Mean % CR/PR of all 11 individual series: 29% (range 0-59%). 
*Therapy with initial loading course (days 1-3 and 8-10). 
doxorubicin i  weekly low-dose schedules inorder 
to achieve a low toxicity profile with preserved ac- 
tivity. Subjective side effects, gastrointestinal tox- 
icity, and alopecia were mild with this combination 
therapy, but leukopenia regularly needed post- 
ponement of the chemotherapy. In spite of these 
clear toxic effects on bone marrow function, the 
combination of weekly low-dose mitoxantrone 
and doxorubicin showed 'moderate' antitumor ac- 
tivity (14% PR) as second-line chemotherapy in 
patients with metastatic breast cancer. However, in 
an additional 29% of the patients aSD was observ- 
ed for 11+-60 weeks with nearly the same median 
duration of progression-free survival as for partial 
responders (28 vs 34 weeks). This median duration 
of SD (about 6-7 months) in our patients is not dif- 
ferent from that of the objective responders eport- 
ed in the other studies (Table 4 and 5), i.e. 6-7 
months. The overall response rate (CR/PR/SD) of 
43% also is generally not different from that re- 
ported in other studies, even in comparison with 
high-dose mitoxantrone 3-weekly in the first-line 
(40%) as reported by Harris et al. [29]. 
Striking in our study was the clear dose-limiting 
bone marrow depression i spite of the low dosag- 
es of the drugs used. However, it has to be noted 
that the relatively high incidence of leukopenia 
compared to 3-weekly schedules i influenced by 
the frequent weekly measurement of WBC in this 
weekly dose regimen. 
In vitro studies with the combination of both 
drugs had suggested a possible protective effect of 
mitoxantrone towards doxorubicin-induced car- 
diotoxicity [26]. This possible protective ffect of 
mitoxantrone towards doxorubicin-induced car- 
diotoxicity, however, was not observed in two clin- 
ical studies that combined the drugs in 3-weekly 
'high-dose' schedules [30, 31]. From our study we 
cannot make definite conclusions in this respect. 
Although 4 patients howed a significant relative 
decrease (16-20% of the pretreatment value) of 
LVEE none of them decreased below an absolute 
value of 50% with the exception of the patient with 
previous mediastinal irradiation and carcinoma- 
tous pericarditis. 
It can be concluded that second-line combina- 
tion treatment of weekly low-dose mitoxantrone 
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plus doxorubicin is a well tolerated rug regimen 
for patients with CMF-resistant tumors, The anti- 
tumor efficacy is comparable to that of other sec- 
ond-line chemotherapeutic regimens in the ab- 
sence of serious ide effects, but postponement of 
drug administration was regularly needed because 
of the occurrence of leukopenia. 
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